PRRUF — IMMUTEP Ltd

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1506184 ·
Last close
$0.02
Market Cap
$29.47M
52W High
$0.33
52W Low
$0.02
ADV30
673
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 83,267,229 63,672,558 21,734,183
Mar 2026 — — — — — — —
Dec 2025 — — — — 147,201,896 72,747,858 48,303,108
Mar 2025 — — — — — — —

Balance + Analyst (yfinance extras)

Retained Earnings
$-520,796,399
Inventory
—
Receivables
$9,623,374
ST Investments
$5,200,486
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$19,934,102
EBITDA
$-79,403,952
Free Cash Flow
$-36,994,360
Enterprise Value
$-11,971,481
Total Cash
$68,873,040
Total Debt
$1,047,526
Shares Out
1,473,721,306
Trailing EPS
$-0.04
Book Value
$0.05
ROE
-77.3%
ROA
-42.5%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Jun 2026 14,556,923 -81,592,146 -79,304,563 83,267,229 21,734,183 61,533,046 —
Jun 2025 — — — — — — —
Jun 2024 0 -46,557,462 -42,716,625 201,579,281 12,057,539 189,521,742 —
Jun 2023 0 -41,431,305 -39,896,348 147,448,990 10,979,601 136,469,389 —
Jun 2022 170,369 -33,837,338 -32,210,826 102,169,550 8,092,184 94,077,366 -43,944,386

Peers — same industry

TickerNameMarket CapLastDaily %
NNVC NANOVIRICIDES, INC. $29.61M $1.16 —
AYTU AYTU BIOPHARMA, INC $28.91M $2.66 —
RDPTF Radiopharm Theranostics Ltd $28.89M $0.01 —
PMN ProMIS Neurosciences Inc. $28.88M $3.21 —
RLFTY MindMaze Therapeutics Holding SA $30.24M $0.18 —

News headlines (Yahoo Finance, 1h cache)

Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma
2026-11-19 00:12 · Yahoo
Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies
2026-11-10 23:48 · Yahoo
IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
2026-11-08 22:34 · Yahoo
Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026
2026-11-05 13:00 · Yahoo
Immutep Quarterly Activities Report Q1 FY27
2026-10-29 12:00 · Yahoo
Immutep Receives A$2.16 million French R&D Tax Incentive
2026-10-28 12:00 · Yahoo
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
2026-10-23 12:00 · Yahoo
Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026
2026-10-19 12:00 · Yahoo
Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research
2026-10-14 12:00 · Yahoo
Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-10-13 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.